AZN · Astrazeneca plc
United States · RS rating 80 · As of 2026-11-03
| Price | 183.88 USD |
|---|---|
| 1-day change | -1.4% |
| RS rating (overall / 1M / 3M / 12M) | 80 / 92 / 85 / 62 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 40 / 32 / 65 |
| Industry group (rank) | Medical-Diversified (4) |
| EPS growth Q/Q | +32.2% |
| Sales growth Q/Q | +2.0% |
| Distance from 52-week high | +12.2% |
| Market cap (USD) | $298.1B |